174 related articles for article (PubMed ID: 27765142)
1. Affordability of adult HIV/AIDS treatment in developing countries: modelling price determinants for a better insight of the market functioning.
Sagaon-Teyssier L; Singh S; Dongmo-Nguimfack B; Moatti JP
J Int AIDS Soc; 2016; 19(1):20619. PubMed ID: 27765142
[TBL] [Abstract][Full Text] [Related]
2. An analysis of volumes, prices and pricing trends of the pediatric antiretroviral market in developing countries from 2004 to 2012.
Lee JSF; Sagaon Teyssier L; Dongmo Nguimfack B; Collins IJ; Lallemant M; Perriens J; Moatti JP
BMC Pediatr; 2016 Mar; 16():41. PubMed ID: 26979974
[TBL] [Abstract][Full Text] [Related]
3. Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?
Meiners C; Sagaon-Teyssier L; Hasenclever L; Moatti JP
PLoS One; 2011; 6(8):e23478. PubMed ID: 21858138
[TBL] [Abstract][Full Text] [Related]
4. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries.
Waning B; Diedrichsen E; Moon S
J Int AIDS Soc; 2010 Sep; 13():35. PubMed ID: 20840741
[TBL] [Abstract][Full Text] [Related]
5. Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America.
Wirtz VJ; Santa-Ana-Tellez Y; Trout CH; Kaplan WA
Health Policy Plan; 2012 Dec; 27(8):638-48. PubMed ID: 22367770
[TBL] [Abstract][Full Text] [Related]
6. Trends and economic stress: a challenge to universal access to antiretroviral treatment in India.
Dhamija P; Bansal D; Medhi B
Curr HIV Res; 2009 Jul; 7(4):410-7. PubMed ID: 19601776
[TBL] [Abstract][Full Text] [Related]
7. A method for understanding generic procurement of HIV medicines by developing countries with patent protection.
Beall RF; Attaran A
Soc Sci Med; 2017 Jul; 185():118-126. PubMed ID: 28578209
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral purchasing and prescription practices in Mexico: constraints, challenges and opportunities.
Chaumont C; Bautista-Arredondo S; Calva JJ; Bahena-González RI; Sánchez-Juárez GH; González de Araujo-Muriel A; Magis-Rodríguez C; Hernández-Ávila M
Salud Publica Mex; 2015; 57 Suppl 2():s171-82. PubMed ID: 26545133
[TBL] [Abstract][Full Text] [Related]
9. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
[TBL] [Abstract][Full Text] [Related]
10. Reforming antiretroviral price negotiations and public procurement: the Mexican experience.
Adesina A; Wirtz VJ; Dratler S
Health Policy Plan; 2013 Jan; 28(1):1-10. PubMed ID: 22375026
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing global antiretroviral procurement prices.
Wirtz VJ; Forsythe S; Valencia-Mendoza A; Bautista-Arredondo S
BMC Public Health; 2009 Nov; 9 Suppl 1(Suppl 1):S6. PubMed ID: 19922690
[TBL] [Abstract][Full Text] [Related]
12. HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare?
Chien CV
PLoS One; 2007 Mar; 2(3):e278. PubMed ID: 17372625
[TBL] [Abstract][Full Text] [Related]
13. Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases.
Waning B; Kaplan W; King AC; Lawrence DA; Leufkens HG; Fox MP
Bull World Health Organ; 2009 Jul; 87(7):520-8. PubMed ID: 19649366
[TBL] [Abstract][Full Text] [Related]
14. Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets.
Waning B; Kyle M; Diedrichsen E; Soucy L; Hochstadt J; Bärnighausen T; Moon S
Global Health; 2010 May; 6():9. PubMed ID: 20500827
[TBL] [Abstract][Full Text] [Related]
15. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
[TBL] [Abstract][Full Text] [Related]
16. The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children.
Waning B; Diedrichsen E; Jambert E; Bärnighausen T; Li Y; Pouw M; Moon S
BMC Pediatr; 2010 Oct; 10():74. PubMed ID: 20950492
[TBL] [Abstract][Full Text] [Related]
17. Does the market share of generic medicines influence the price level?: a European analysis.
Dylst P; Simoens S
Pharmacoeconomics; 2011 Oct; 29(10):875-82. PubMed ID: 21797288
[TBL] [Abstract][Full Text] [Related]
18. Do national drug policies influence antiretroviral drug prices? Evidence from the Southern African Development community.
Liu Y; Galárraga O
Health Policy Plan; 2017 Mar; 32(2):170-177. PubMed ID: 28207060
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral drug expenditure, pricing and judicial demand: an analysis of federal procurement data in Brazil from 2004-2011.
Luo J; Oliveira MA; Ramos MB; Maia A; Osorio-de-Castro CG
BMC Public Health; 2014 Apr; 14():367. PubMed ID: 24735589
[TBL] [Abstract][Full Text] [Related]
20. Can voluntary pooled procurement reduce the price of antiretroviral drugs? a case study of Efavirenz.
Kim SW; Skordis-Worrall J
Health Policy Plan; 2017 May; 32(4):516-526. PubMed ID: 28052986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]